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Introduction
Mental illness is common among HIV-infected
individuals.  Outpatient studies of un-incarcerat-
ed HIV-infected patients reveal a prevalence as
high as 54% for Axis I psychiatric disorders
(major depression, bipolar disorder, schizophre-
nia and obsessive compulsive disorder) and
26% for Axis II psychiatric disorders (personali-
ty disorders).1 Among the incarcerated, data
from the United States (US) Bureau of Justice
Statistics indicate that over 16% of all state
prison and jail inmates have a mental or emo-
tional condition, 10% receive psychotropic med-
ication and 12.5% participate in mental health
therapy or counseling.2 Given the high preva-
lence of psychiatric disorders among those with
HIV infection, as well as among the incarcerat-
ed, it is likely that a significant proportion of HIV-
infected inmates are suffering from one or more
mental illnesses.  
Mental illness complicates the management of
HIV infection in several ways.  First, studies
have shown that mental illnesses, especially
depression, contribute to treatment non-adher-
ence and poor HIV outcomes.3 Second,
patients with mental illness are less likely to be
prescribed certain treatments including hepatitis
C virus (HCV) therapy and highly-active anti-
retroviral therapy (HAART) in many settings,4
despite new data suggesting that patients with
mental illness who receive treatment for the
mental illness achieve HIV clinical outcomes
equal to or better than HIV-infected control
patients without mental illness.5 Lastly, mental
illness, when sub-optimally treated, has been
associated with behaviors that risk transmission
of HIV. 6,7,8
A key to improving outcomes in HIV-infected
populations is adequate detection and treat-
ment of mental illnesses.  At the very minimum,
HIV providers should be familiar with the
screening and management of the most com-
mon mental illness among HIV-infected patients
- depression.  Reviews on the management of
depression, including in HIV-infected patients,
have been recently published.6,9 In this article
we highlight diagnostic and therapeutic
approaches to depression among HIV-infected
incarcerated persons.  
Screening for Depression
Despite the high prevalence of depression, this
disorder is under-diagnosed and under-treated.
A major challenge to the clinician is the differen-
tiation between major depression and isolation,
demoralization and reactive states of grief and
loss associated with negative experiences -
including the diagnosis of HIV infection and/or
incarceration. In addition, establishment of a
diagnosis of depression is complicated by the
overlap between symptoms that could suggest
depression, but could also be secondary to HIV
disease or attendant opportunistic conditions.
Indeed, the differential diagnosis that must be
considered during the work-up of depressive
symptoms in the HIV-infected inmate is exten-
sive, and is discussed in detail below.  
Depression may manifest predominantly as
somatic complaints.  Although readily ascribed
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to underlying HIV disease, symptoms such
as abdominal pain, fatigue, insomnia, inex-
plicable muscle or visceral pain and atypi-
cal cardiac symptoms have been found to
be more likely due to depression than
advancing HIV disease, especially in
patients with relatively high CD4 T-cell
counts.10 Data among non-incarcerated
individuals suggest men and women with
depression present with similar complaints,
though women are more likely to report
anxiety, somatization, increased appetite,
increased weight, increased sleep and hos-
tility.11
In the setting of HIV infection, screening for
depression can be aided by the use of
standardized scales.  We have validated
two screening tools - the General Hospital
Questionnaire (GHQ) and the Beck
Depression Inventory (BDI) in HIV-infected
individuals.  In a study of outpatients with
HIV infection, any patient who scored
above six points on the GHQ and above 14
points on the BDI was found to have a high
likelihood of major depression when evalu-
ated by a psychiatrist.1 Thus, a patient who
breaches these thresholds on both instru-
ments should be evaluated thoroughly to
determine the type of depressive illness he
or she is experiencing.  
Patients with a complaint of depression
usually suffer from either endogenous
depression (also known as major depres-
sion), or reactive depression (also known
as adjustment disorder or demoralization).
A third diagnosis, dysthymia, is less com-
mon.  Patients with major depression are
less able to experience pleasure from plea-
surable stimuli, a state known as anhedo-
nia, and in any given setting the patient will
be less able or unable to feel pleasure.  A
simple analogy is that for patients with
major depression, the experience is as if
the electrical outlet is not connected to the
wires carrying the current - no matter what
you plug in or when you try it, there is no
power. In contrast, patients with a reactive-
type depression are depressed about
something, and therefore can experience
pleasure when distracted from the circum-
stance or event that is upsetting.  In this
instance, it is as if the electrical outlet is
controlled by a switch - when the switch is
off because the patient is in the depressing
setting (e.g., at home, in jail or prison, in the
HIV clinic, etc.), there is no power, but
when the switch is on because the patient
is distracted from the depressing setting,
the power flows normally.  
In a very simple categorization, major
depression is a brain disease in which the
ability to feel pleasure is broken in a perva-
sive and persistent manner, while adjust-
ment disorders are psychological impair-
ments in which the patient's meaningful
experiences of life's events and circum-
stances cause an understandable bad
mood.  
Understanding this basic premise of major
depression allows for a greater under-
standing of the experience of life by a
depressed person.  One may try to imagine
a life in which nothing felt good.  Food does
not have much flavor, sleep is not restful,
friends and family bring no joy, sex is not
pleasurable and one's usual enjoyable
activities are no longer fun.  Further, with-
out pleasurable inputs allowing one to inter-
pret one's actions as successful and uplift-
ing, one quickly comes to expect that every
action will lead to either numbness or pain.
Hopelessness ensues. Major depression
driven suicide kills thousands of people
who have fallen to despair and have begun
to believe that nothing will ever go right
again.  Of course, things do go right all the
time, but the depressed person cannot
experience the pleasure that other people
and life have to offer - to return to the anal-
ogy, it is as if the outlet has been discon-
nected from the electricity.
When assessing a patient with a complaint
of depression, it is therefore important to
ask about pleasurable experiences.  In a
correctional setting, pleasurable experi-
ences may be limited, but an interviewer
open to exploring a patient's daily routines
may discover several activities that result in
good feelings if the patient does not have
anhedonia (e.g., playing ball, talking with
friends, watching television, playing cards,
visiting with relatives/friends, reading, etc).
Furthermore, it is often very useful to obtain
input from an outside observer, when pos-
sible.  If a patient will consent, the inter-
viewer could contact a family member or
friend to determine how the patient appears
to feel when interacting with him or her
(e.g., on the phone, during a visit, etc).  
It is likewise important to explore any of the
patient's interpretations of his or her
depression fully, without allowing the inter-
viewer's attitudes about the complaint to
interfere.  Such is the case, for example,
when a patient reports depression about
having HIV infection.  Just because the
interviewer might feel it would be devastat-
ing to have HIV, one cannot assume the
patient shares those feelings exactly.  For
many incarcerated individuals, being diag-
nosed with HIV was not the most devastat-
ing life experience that they have endured.
He or she may be reacting to an entirely dif-
ferent aspect of the illness, or may be
reporting he or she is upset about the ill-
ness when nothing, in fact, has changed.
By saying the cause of the depression is
HIV-related, the patient may be trying to
explain depressive symptoms in an under-
standable way.  Likewise, inmates may
attribute a host of depressive symptoms to
being incarcerated - restriction of activities
resulting in less pleasure, other inmates'
activities interrupting sleep, cafeteria food
taste causing loss of appetite, etc.  In this
way, a major depressive episode could be
missed if the questions do not inquire
deeply enough about the experiences to
which negative feelings are attributed.
When major depression is diagnosed,
assessment should be made for suicidal
ideation (see Case #1 in this month's Case
Series). Assessment includes past mental
health history including prior suicide
attempts, symptoms of psychosis (voices
commanding the patient harm him/herself),
plans for suicide (patients with specific plan
for how to accomplish suicide are at greater
risk), beliefs regarding HIV disease pro-
gression and current life stressors.
Differential Diagnosis of Depression in
HIV-Infected Patients
Depressive symptoms in the HIV-infected
inmate may well indicate the presence of
major depression, but as CD4 T-cell count
decreases, concern for alternative infec-
tious, metabolic and medication causes
increases.  The differential diagnosis
includes dementia, delirium, central ner-
vous system (CNS) illnesses (e.g., lym-
phoma, toxoplasmosis, neurosyphilis, cryp-
tocococcal meningitis), metabolic diseases
(e.g., hypothyroidism, hypogonadism),
acute medical illnesses, substance abuse,
cocaine withdrawal and medication side
effects (e.g., interferon, efavirenz, beta-
blockers, metoclopramine), among others.  
Infectious and opportunistic conditions can
be assessed as is appropriate given the
clinical stage of the patient and other sug-
gestive symptoms and signs.  In all patients
with depressive symptoms it is crucial to
examine for abnormalities of the thyroid
axis in men and women and testosterone
levels in men.  Patients should be queried
for symptoms of these conditions and basic
laboratory studies should be done at least
annually to detect sub-clinical abnormali-
ties.  Correction of hypothyroidism and
hypotestosteronemia is often necessary to
achieve remission from major depres-
sion.12,13
In any case where major depression is sus-
pected, probing for symptoms of bipolar
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Dear Corrections Colleagues,
A substantial proportion of persons living with HIV infection in the United States are incarcerated
and among these,  many - if not the great majority - suffer from psychiatric illnesses.  Mental illness
places people at risk for acquiring HIV and for those already HIV-infected, complicates treatment
and prevention efforts.  As most of us have observed, abuse of alcohol, cocaine, heroin and other
illicit substances is often a form of self-treatment among the depressed and traumatized, increas-
ing not only their odds for infection with HIV and viral hepatitis, but also for incarceration.  In this
issue of the IDCR, Drs. Andrew Angelino and Glenn Treisman, psychiatrists leading Psychiatric
Services for the Johns Hopkins HIV/AIDS Care Program, provide a guide to the diagnosis and
treatment of the most prevalent mental health disorder of HIV-infected individuals - major depres-
sion.  Drs. Angelino and Triesman have authored a useful book, "The Psychiatry of AIDS", avail-
able in paperback and a "must-read" for HIV health care providers - particularly those in correc-
tions.  Their article is complemented by a series of illuminating cases from Dr. Jeffery Watts,
Psychiatric Medical Director at the CORE Center, a large clinic specializing in mental health care
for HIV-infected patients which is associated with Cook County Hospital in Chicago.
I hope this issue, my first as editor, will raise awareness of the need to screen all HIV-infected
inmates for mental illnesses and provide a starting point for continued clinician education on the
detection and management of mental health disorders in correctional settings.  Reading this issue
has made it clear to me that the benefits patients can accrue when their psychiatric illnesses are
addressed is multiple and includes improved quality of life, enhanced medical adherence, reduced
substance abuse and adoption of HIV transmission prevention measures.  After reading this issue,
individuals should be able to differentiate between major depression and reactive states which can
produce depressive symptoms, appreciate the differential diagnosis of depression in the HIV-
infected inmate and understand the approaches to the pharmacologic and psychotherapeutic treat-
ment of depression in such patients.
In closing, I wish to thank you for the work you do, often in a difficult environment with patients who
do not always appreciate the value of the help you are offering.  The IDCR staff, including the edi-
torial board of experienced and insightful providers in correctional health care, aim to provide you
with the information you need to continue to deliver high quality care.  During the next year we will
address topics most relevant to your work and will enhance our website to provide clinical
resources we hope you will find useful.  We can best accomplish these aims with feedback from
you, our readers.  Feel free to email me regarding the content of the IDCR at wohl@med.unc.edu.
Thanks,
David Alain Wohl, MD
LETTER FROM THE EDITOR
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disease, specifically symptoms of mania,
should be performed given differences in
the management of these disorders.
There is some evidence that HIV infection
itself directly causes major depression.
First, there is a higher prevalence of major
depression in HIV-infected patients than in
the general population, as previously stat-
ed.  Second, there is a correlation between
progression of HIV disease and develop-
ment of major depression.  This, taken in
concert with models for depression caused
by chronic CNS inflammation (likely medi-
ated by both pro- and anti-inflammatory
cytokine action in CNS glial cells),14
demonstrates a possible causal relation-
ship for HIV infection and major depres-
sion.
In addition to the direct effects of HIV and
inflammation on the brain causing major
depression, medications can cause or
worsen depression.  Two medications in
particular, efavirenz and alpha-interfer-
on15,16,17 (the latter used to treat HCV, fre-
quently comorbid with HIV - particularly in
correctional settings) can cause depressive
symptomatology.  In general, depressive
symptoms that begin after these medica-
tions are started should raise suspicion for
a causal relationship.  This may be over-
looked, however, since the depressive
symptoms often take some time to develop.
While the time course for efavirenz is less
clear, depressive symptoms develop
between one and 24 weeks after starting
treatment with alpha-interferon, with a
mean of eight to 12 weeks after first dose.
Screening for depression prior to initiation
of alpha-interferon and regularly during
therapy is prudent and should be incorpo-
rated into the management of HCV infec-
tion.
Treatment
The best news for patients with major
depression from any cause is that it is usu-
ally a very treatable condition.  In studies of
HIV-infected depressed patients, up to 85%
had at least some improvement with treat-
ment within 12 weeks and 50% returned to
baseline.6,18 The overall response rate for
alpha-interferon-induced depression in the
literature is likewise approximately 85%.16
The cornerstone of effective treatment for
major depression is anti-depressant med-
ication.  All available standard anti-depres-
sant therapies have a potential efficacy for
treatment of major depression co-morbid
with HIV and/or alpha-interferon therapy.
Selection of an agent is therefore based
primarily on tolerability.  In general, anti-
depressants with few side effects experi-
enced by the patient may promote adher-
ence to the medications, and therefore,
may have a good chance at effective treat-
ment.  Treatment should be started at low
doses and titrated upward to minimize the
risk of adverse effects.  An algorithm for the
management of depression and a listing of
variables to consider when prescribing an
antidepressant are shown in this month's
IDCR-o-gram.  
As the efficacy of the various classes of
anti-depressants is similar, the search for a
good match between the patient and treat-
ment can be informed by the properties of
the agents and the patient's medical and
psychiatric symptoms.  For example, tri-
cyclic anti-depressants, such as nortripty-
line, doxepin and desipramine, often curb
diarrhea, promote sleep and assist with
weight gain - all of which may be desirable
for certain patients.  Some selective sero-
tonin-reuptake inhibitors (SSRIs) (e.g., flu-
oxetine and escitalopram), venlafaxine XR,
bupropion SR and XL often cause some
activation, thus eliminating fatigue.
Bupropion SR may also be useful in combi-
nation with smoking cessation programs,
since it treats symptoms of nicotine with-
drawal.  Venlafaxime XR may reduce
chronic pain.  Matching the side effect pro-
file of the medication to the patient's pre-
senting symptoms can be useful in promot-
ing adherence, thus enhancing the likeli-
hood of a therapeutic effect.  An excellent
review of the properties of anti-depressants
has been recently published.9
An additional consideration when choosing
an anti-depressant for an HIV-infected
patient are interactions with current med-
ications and those that are likely to be pre-
scribed in the future.6 The IDCR published
a review of drug-drug interactions between
mental health and HIV medications in
January 2005, available at
www.IDCRonline.org.19 SSRIs, like many
protease inhibitors, are metabolized via the
cytochrome P450 system.  Ritonavir, in par-
ticular, is an extremely potent inhibitor of
the P450 enzymes.  Nevirapine can induce
the P450 system, producing relatively
decreased SSRI levels.  Therefore, there is
a potential for drug interactions that can
alter SSRI levels; however, in general, the
majority of interactions between SSRIs and
antiretroviral fail to be clinically significant,
and this information is presented to alert
potential prescribers of a mechanism for
those rare cases of clinically-significant
interactions.  Again, starting with lower
doses of the anti-depressant will reduce the
risk of supratherapeutic plasma drug levels
and adverse effects and permit titration to
doses that are tolerated and effective.  
Following the initiation of anti-depressant
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Case # 1: Management of depression in
the HIV-infected patient
A 46 year-old African-American male co-
infected with HIV and Hepatitis C virus
(HCV) presents for his routine medical
appointment.  Incarcerated for the past
three years, he often reports sadness and
irritability, but has been reluctant to "take
another pill."  He is prescribed a twice-daily
regimen of Combivir and Kaletra and has
achieved an undetectable viral load and
CD4 cell count of 750 cells/mm3.  This
inmate has a past history of intravenous
"speedballing" of heroin and cocaine, but
denies prior psychotropic medication trials.
With the death of his mother three months
ago, he complains of a progression of his
depression with persistent low mood, fre-
quent anger episodes, insomnia with early
morning awakening and passive thoughts
of dying.  He seems despondent but sin-
cere in his presentation and assertions of
safety.  He is now agreeable to help, includ-
ing medication, if necessary.
Case # 1: Questions
How would you manage his depression and
thoughts of dying?  Does his current anti-
retroviral regimen impact the selection of
antidepressant or dosage?
Continued on page 5
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Case # 1: Discussion
The first consideration must be patient
safety.  Many facilities would immediately
place this person on suicide precautions or
monitoring.  However, past suicidal history,
current intent and/or plans to harm himself,
and his level of anxiety should be assessed
when devising the safety management
plan.  Careful probing to determine each of
these can assist the provider in determining
whether or not the patient is currently a risk
to himself. 
The next assessment centers on his
depression.  Although bereavement is a
possibility in the differential diagnosis, the
extent and duration of his symptoms are
consistent with major depression.
Treatment of major depression in HIV/AIDS
has been widely studied throughout the
AIDS epidemic.  The estimate of the lifetime
prevalence of major depression in persons
with HIV is 50%, greatly exceeding that of
the general population.  Medication man-
agement of depression usually results in
60-70% response within four to eight weeks
and remission in eight to 12 weeks.
Patients and clinicians alike often have
expectations of faster outcomes.
Antidepressant selection in HIV/AIDS
patients is simpler than other psychotropic
classes.  Most selective serotonin reuptake
inhibitors (SSRIs) and tricyclics (TCAs)
have shown similar efficacy and side effect
profiles to the general population.  Although
mild interactions between ritonavir-contain-
ing regimens and some antidepressants
may occur, (generally leading to increased
levels of the antidepressants) most clini-
cians should feel comfortable and safe in
starting an antidepressant in this otherwise
stable HIV patient.  Since efficacy is essen-
tially equivalent in the spectrum of antide-
pressants, formulary availability and side
effect profiles usually dictate the selection.
Drug selection is less important than dura-
tion of treatment.  Antidepressant medica-
tions should be continued for at least six to
nine months after remission of the depres-
sive symptoms.  The patient should be
monitored for the development of side
effects initially every two weeks and effec-
tiveness of treatment assessed eight to 12
weeks after starting antidepressant therapy.
Continued follow-up every three to four
months thereafter is standard.  
In addition to the challenge the dual diag-
noses of HIV and major depression present
to this patient, as well as his clinicians, HCV
co-infection further complicates the situa-
tion.  Interferon used in the treatment of
HCV infection can exacerbate depression.
However, a history of depression is not an
absolute contraindication for HCV therapy
and patients with well controlled depression
may be candidates for such treatment in
coordination with a psychiatrist. 
Case # 2: Management of co-morbid HIV
and severe mental illness
A 35 year-old Caucasian male has been a
frequent recidivist in the correctional setting
and is newly incarcerated.  Diagnosed with
schizophrenia, his co-morbid cocaine
abuse and homelessness have contributed
to his recent HIV infection and diagnosis
prior to this incarceration.  He has yet to
receive antiretroviral medications and is
unaware of any prior laboratory information.
Past corrections' records indicate various
psychotropic trials but the patient indicates
that he receives haloperidol (Haldol), car-
bamazepine (Tegretol) and benztropine
(Cogentin) from the local emergency room
when needed.  He remembers having a
seizure after a head wound three years
ago, but denies any seizures since that
time.  He currently has a flat affect and a
poverty of thought (e.g. speech is limited to
few words).  Staff reports that he is paranoid
around other inmates over the past few
days.  His last reported date of cocaine use
was two months ago.  
Case #2: Questions
What is the recommended approach in the
treatment of severe mental illness in per-
sons with HIV?  What is the recommended
approach of antiretroviral treatment in the
severe mentally ill?
Case #2: Discussion
As always, the need for coordinated care
between psychiatry and HIV primary care is
essential.  In these situations with two
severe disease processes, a prioritization
in treatment should follow the basic assess-
ment of the mental illness (diagnosis, cur-
rent symptoms, level of dysfunction, co-
morbid substance abuse) and HIV status
(viral load, CD4 count, current symptoms).
In this case, the patient's recent HIV infec-
tion would not likely need immediate anti-
retroviral medication; however he does
need immediate psychiatric treatment.  
Although the psychiatrist would prescribe
the antipsychotic in this case, some impor-
tant items are presented here.  First, the
history and collaborative information would
be helpful to ensure the diagnosis of schiz-
ophrenia is correct.  The current mental sta-
tus exam and the remote last cocaine
usage make a cocaine-induced psychotic
disorder unlikely as the sole diagnosis. But
in patients with more recent cocaine expo-
sure, this diagnosis must be considered.  
In regards to treatment, "typical" antipsy-
chotics or "older" neuroleptics have a high-
er propensity for hyperprolactinemia, tar-
dive dyskinesia, and extrapyramidal side
effects (EPS) including dystonias (involun-
tary muscle contractions), akithisia (rest-
lessness, fidgeting) and parkinsonism.   In
patients with HIV/AIDS, this rate may be
increased three-fold, reportedly due to the
predilection of the HIV virus for the basal
ganglia and associated areas of the brain.
Furthermore, medications to minimize EPS
symptoms such as diphenhydramine
(Benadryl) and benztropine (Cogentin)
often worsen cognitive functioning due to
the anticholinergic effects of these drugs.
Newer, or "atypical", antipsychotic medica-
tions are considered treatments of choice
for schizophrenia but may carry increased
risks of the metabolic syndrome with hyper-
lipidemia and/or non-insulin dependent dia-
betes mellitus (NIDDM).  In particular, stud-
ies have most closely linked olanzapine
(Zyprexa) to these problems, although all
agents in this class carry the warning in
their package insert.  The NIDDM is not
directly associated with the increase in
patient weight with the initiation of the drug.
One of the six atypical agents (Clozaril) can
cause agranulocytosis and is not usually
considered in HIV patients.  Two of the
remaining five agents (Geodon and Abilify)
are CYP p450 3A4 substrates, which may
create challenges to future antiretroviral
management, particularly ritonavir-contain-
ing regimens.  Risperidone (Risperdal) or
queitapine (Seroquel) might be the best
choices in this patient.  Risperidone is now
available in a depot injection form
(Risperdal Consta) that may be adminis-
tered every two weeks in non-adhering
patients.  Due to the timing of antiretroviral
treatment, potential drug interactions, and
the need for metabolic monitoring (glu-
cose/lipid), ongoing coordination between
the HIV provider and the psychiatrist will
continue to provide the best possible out-
come for this patient.
Summary
The challenges in the management of men-
tal illness and HIV in the correctional setting
may seem overwhelming.  These cases
demonstrate that a thorough history, initial
physical examination and basic mental sta-
tus assessment will provide you the needed
tools for diagnosis, initial management, and
psychiatric referrals.  Although potential
drug interactions are overwhelming at times
to remember, the key to management and
monitoring is in coordination with knowl-
edgeable pharmacists and psychiatrists to
ensure patient safety and positive patient
outcomes.
CASE SERIES
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therapy, the patient should be assessed
every two weeks initially, at first for moni-
toring of side effects and later for efficacy.  It
may take six weeks to notice a significant
change in depressive symptoms and
patients should be counseled not to expect
rapid results.  Once remission in depres-
sion is achieved, the dose of the anti-
depressant should not be altered.  
Failure to achieve an effect should lead to
reassessment of the diagnosis.
Suboptimal dosage, drug-drug interactions
and/or poor medication adherence may
have contributed to the failure.  If these are
ruled-out, then a switch to another agent
can be attempted.  Response rates to a
second SSRI after failure to respond to a
drug in this class are 60-70%.11 In cases
where a partial effect is seen during initial
anti-depressant therapy, the patient may be
a candidate for augmentation with a second
agent with a slightly different neuropharma-
cological profile (e.g., adding venlafaxine or
bupropion to an SSRI).  There is a fair
amount of evidence suggesting that lithium
carbonate is an effective augmenting agent
which can be monitored by serum levels.20,21
Anti-psychotic medications are also very
useful in this regard.  In particular, olanzap-
ine22 promotes sleep and weight gain and
ziprazidone provides a nice "energy boost"
in lower doses (but must be taken with food
to be effectively absorbed in the stomach).23
All patients with treatment-resistant depres-
sion should be referred to a psychiatrist.  
It is important to remember that anti-
depressant medications themselves will
only affect a person's ability to feel plea-
sure.  Psychotherapy is an integral part of
the treatment of major depression and is
more effective when combined with phar-
macological therapy than when either is
used alone.24 Returning to the electric out-
let analogy, anti-depressants will turn on
the power to the outlet.  The patient's atti-
tudes about the use of electric appliances
may be unaffected - he or she may believe
that life contains no pleasures or that plea-
sures are fickle and subject to disappear
without notice.  This is the reason for com-
bining psychotherapy with anti-depressant
medication.  Psychotherapy is the process
of changing the patient's assumptions,
behaviors and feelings about the world
through discussion, exploration and prac-
tice.  In essence, a depressed patient has 
to gain insight that the experiences he or
she had while depressed were inherently
biased because of a brain disease disal-
lowing the experience of pleasure, and that
new experiences, now that the power is
back on, will be different.  In this way, trials
of behaviors once thought to be unreward-
ing may result in regained pleasures and
thus, generate a sense of hope.  
Several clinical studies have demonstrated
enhanced efficacy of the treatment of
depression in HIV-infected patients with
psychotherapy25,26,27 and correctional sys-
tems with access to psychiatric consultation
and on-going appropriate counseling ser-
vices for patients with major depression
have a distinct advantage in their ability to
treat this disorder.  For patients who are
about to be released, post-release commu-
nity counseling and mental health care
should be arranged.
In all cases, there needs to be coordination
among HIV care providers and those pro-
viding psychiatric care to ensure that each
is aware of alterations in the status of the
patient, modifications in treatment or
dosage, potential for drug interactions and
the development of relevant treatment-
related adverse effects.
Conclusion
HIV infection and major depression are
prevalent and often co-morbid conditions
among inmates in the U.S.  Health care
providers practicing in the correctional set-
ting are most effective when they can accu-
rately diagnose and treat major depression
in HIV-infected inmates.  Following the gen-
eral principles in this article will assist
health care providers to diagnosis depres-
sion and differentiate between this disorder
and other conditions that can cause
depressive symptomatology, choose treat-
ments that are tailored to the patient and
recognize the potential for toxicity and drug
interactions.  Psychiatric consultation
should be sought for patients with treat-
ment-resistant depression, such as those
failing a second anti-depressant.  In addi-
tion, psychotherapy is an important comple-
ment to pharmacologic therapy and should
be a component of the treatment of major
depression in the HIV-infected inmate.
Coordination between clinicians providing
HIV care and those providing psychiatric
care is essential to the safe and effective
management of shared patients.
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MENTAL HEALTH 101
Selection of a First Line Antidepressant Medication
Variable
Patient history
Age group
Children and adolescents
Adults < 65 yr
Adults > 65 yr
Family history of response
Past response
Depression characteristic
Bipolar depression
Psychotic depression
Depression with features of
obsessive-compulsive disorder
Panic attacks
Agitated depression
Depression with psychomotor
retardation
Medication-resistant depression
Coexisting medical conditions
Heart disease
Stroke
Pain
Concern regarding side effects
Gastrointestinal symptoms
Anticholinergic symptoms
Sexual dysfunction
Weight gain
Postural hypotension
Diabetes
Medication
SSRI* (fluoxetine)
SSRI, NRI^ or SNRI**
SRI^^
Same medication that was effective in first-degree relative
Same medication that was effective previously
Mood stabilizer (lithium or lamotrigine) plus antidepressant
Antidepressant plus antipsychotic (atypical)
SSRI
SSRI
Sedating antidepressant
Nonsedating antidepressant (NRI, SSRI)
Electroconvulsive therapy or combination of medications
Nontricyclic antidepressants
Caution with SNRIs or NRIs and blood pressure
Duloxetine, venlafaxine
Nontricyclic antidepressant
Nontricyclic antidepressant
Non-SSRI antidepressant
Avoid atypical antipsychotics
NRI
Avoid atypical antipsychotics
*SSRI = selective serotonin-reuptake
inhibitor
^NRI norepinephrine-reuptake inhibitor
**SNRI = serotonin-norepinephrine
reuptake inhibitor
^^SRI serotonin-reuptake inhibitor.
Table adapted from:
Mann, J.  Drug therapy: the medical
management of depression.  NEJM.
2005; 353(17):1828.
IDCR-O-GRAM: HIV and Major Depression
Criteria for major depression or equivalent 
or convincing other evidence of major depression
Antidepressant therapy with psychotherapy
drug selection paradigm
Tritherapeutic trial (usually 4-6 weeks)
If treatment fails or side effects intolerable change to new drug
(usually new class, but same class or augmentation if strong rationale)
With a partial response limited by maximum dose or toxicity:
Longer trial or augmentation strategy (lithium, neuroleptic,
thyroid hormone, second agent, etc.)
Tricyclic antidepressant as first drug
(Nortiptyline, Doxepin, Deslpramine) (There
are many others with special utility.)
Drugs with special or intermediary properties
(Trazodone, Netazodone, MAOIs,
Bupropion, Mirtazapine, Venlafaxine)
SSRI antidepressant as first drug (Fluoxetine,
Sertraline, Paroxetine, Fluvoxamine,
Escitalopram, Citalopram)
YES
NO
Psychotherapy
Table reprinted with permission from: Treisman G, Angelino A.  The Psychiatry of AIDS: A Guide to Diagnosis and Treatment.  2004; 41
Symptoms of Major Depression
Politics on Paper - Global
Tragedies/Personal Perils.
Featuring the work of Eric
Avery MD, John Risseeuw
and Robbin Ami Silverberg. 
January 13 - March 11, 2006
Columbia College Chicago
Center for Book & Paper Arts
1104 S. Wabash Ave
Chicago, IL 60605
Phone: 312.344.6684
13th Annual Conference on
Retroviruses and
Opportunistic Infections
February 5-9, 2006
Denver, Colorado
Visit:www.retroconference.org
13th Annual Ryan White
National Youth Conference
on HIV/AIDS
February 18-20, 2006
Philadelphia, Pennsylvania
Visit: www.napwa.org/rwnyc/
National Conference on
African-Americans and
AIDS
February 27-28, 2006
Philadelphia, PA
Visit: www.minority-health-
care.com/
NIMH/IAPAC Conference on
HIV Treatment Adherence
March 8-10, 2006
Jersey City, New Jersey
Visit: www.hivadherencecon-
ference.com
Updates in Correctional
Health Care
April 8-11, 2006
Las Vegas, Nevada
Visit: www.ncchc.org
Satellite Videoconference
"Hepatitis B & C with HIV
Co-infection"
April 19, 2006
12:30-2:30 EST
CME-accredited webstream
of last conference available
on-line
Visit: www.amc.edu/patirnt/hiv
/hivconf/index.htm
ACHSA 2006
Multidisciplinary Training
Conference
May 11-13, 2006
Durham, North Carolina 
Visit: www.achsa.org
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Screening Tool for Mental Illness, Substance
Abuse Validated
Pence, et al conducted a validation study of the
Substance Abuse and Mental Illness Symptoms
Screener (SAMISS), a 16-item screening instru-
ment designed to identify substance abuse and
mental illness in HIV-infected patients.  The
Structured Clinical Interview for DSM-IV (SCID)
was used as the reference to evaluate the perfor-
mance of the SAMISS in this study.  The study pop-
ulation was comprised of HIV-infected patients who
had never previously been screened with the
SAMISS.  Of 148 participants who completed fol-
low-up, 37.2% screened positive on the SAMISS
substance abuse (SA) module.  Compared with the
SCID, the SA module of the SAMISS had 86% sen-
sitivity and 75% specificity.  Of 143 participants who
completed SCIDs and complete data information,
69.2% screened positive on the mental illness (MI)
module of the SAMISS.  Compared with the SCID,
the MI module of the SAMISS had 95% sensitivity
and 49% specificity. Study authors concluded that
the SAMISS demonstrated high sensitivity and
moderate specificity as a screening tool for the
identification of SA/MI in this HIV-infected patient
population.  The brevity of the SAMISS makes it
practical for routine use in busy clinical settings, but
should be followed by a more rigorous psychiatric
evaluation for patients who screen positive.
Pence B, Gaynes B, Whetten K, et al.  Validation of
a brief screening instrument for substance abuse
and mental illness in HIV-positive patients.  J Acquir
Immune Defic Syndr.  2005; 40(4):434-44.
Clinician-Delivered Intervention to HIV Patients
Reduces Risk Behaviors
Fisher, et al conducted a prospective clinical trial to
evaluate the effectiveness of a clinician-delivered
intervention in reducing unprotected sexual behav-
ior of HIV-infected patients.  The risk reduction
intervention consisted of brief, patient-centered dis-
cussions, conducted during routine clinical visits,
over a study interval of 18 months.  During these
discussions, clinician and patient negotiated an
individually tailored behavior change, goal or plan.
Sessions concluded with the patient being given a
"prevention prescription" written on a prescription
pad.  Analysis of the intervention demonstrated that
unprotected vaginal, anal and insertive oral sexual
events decreased significantly over time among
HIV-infected patients who received the clinician-
delivered HIV prevention intervention.  By contrast,
the same measures increased significantly over
time for HIV-infected patients in the standard-of-
care control arm.  Study authors concluded that a
clinician-delivered HIV prevention intervention,
implemented during the course of routine clinical
care, can be effective in reducing a broad measure
of HIV-infected patients' unprotected vaginal, anal
and insertive oral sexual behavior.
Fisher J, Fisher W, Cornman D, et al.  Clinician-
delivered intervention during routine clinical care
reduces unprotected sexual behavior among HIV-
infected patients.  J Acquir Immune Defic Syndr.
2006; 41(1):44-52.
Hospitalizations, Expenditures Due to HCV on
the Rise
As the population of patients infected with hepatitis
C virus (HCV) grows older, the treatment burden of
HCV continues to grow.  Grant, et al sought to pro-
vide longitudinal statistics concerning health care
resource use by HCV-infected patients.
Hospitalization trends using the Nationwide
Inpatient Sample (NIS) from the Healthcare Cost
and Utilization Project (HCUP) were examined.
From 1994 through 2001, HCV-related hospitaliza-
tions, hospital days, total charges and deaths
increased at average annual rates exceeding 20%,
more than three-fold higher than rates for all-cause
hospitalizations.  HCV liver causes for all ages
accounted for almost four times as many hospital
days in 2001 as in 1994.  Increasing hospitaliza-
tions and hospital days coincided with higher
expenditures for HCV.  Study authors concluded
that the future burden of HCV infection will match
and may exceed analysts' forecasts.
Grant W, Jhaveri R, McHutchinson J, et al.  Trends
in health care resource use for hepatitis C virus
infection in the United States.  Hepatology.  2005;
42(6):1406-13.
Antidepressant Treatment Improves Adherence
to ART
Untreated depression has been associated with
medication non-adherence.  To evaluate the effect
of anti-depressant treatment (ADT) on antiretroviral
(ART) adherence, Yun, et al., retrieved data from
chart review for 1,713 HIV-infected patients seen at
an urban health care setting.  Of these patients,
57% were depressed and of these, 46% and 52%
received ADT and ART treatment, respectively.
Adherence to ART treatment was lower among
depressed patients not adherent to ADT compared
to depressed patients adherent to ADT.  Study
authors concluded that there may be a benefit of
ADT on ART adherence among depressed HIV-
infected patients.
Yun L, Mavari M, Kobayashi J, et al. Antidepressant
Treatment Improves Adherence to Antiretroviral
Therapy Among Depressed HIV-Infected Patients.
JAIDS.  2005; 38(4):432-8.
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RESOURCES
American Psychiatric Association.
http://healthyminds.org/copingwithaidsandhiv.cfm
Centers for Disease Control and Prevention.
http://www.cdc.gov/hiv/pubs/brochure/care10.htm
Information on Efavirenz:
Annals of Internal Medicine.  2005; 143(10):1-43.
Mental Health AIDS.
http://mentalhealthaids.samhsa.gov/index.asp
National Institute of Mental Health.
http://www.nimh.nih.gov/publicat/dephiv.cfm
National Institute of Mental Health.
http://www.nimh.nih.gov/publicat/index.cfm
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